Work

Targeting DNA Ligase III Addiction in T-Cell Acute Lymphoblastic Leukemia by the Natural Flavonoid Rhamnetin

Year: 2026
Type: article
Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy with dismal outcomes in relapsed/refractory settings, where nelarabine remains the sole approved agent with limited frontline efficacy. Genomic instability in T-ALL is sustained by a rewired DNA repair network, yet the functional reliance on DNA Ligase III (LIG3)-dependent alternative non-homologous end joining remains largely unexplored. By interrogating public transcriptomic cohorts, functional DepMap datasets, and siRNA-mediated knockdown, we evaluated LIG3 expression and essentiality in T-ALL. Pharmacological targeting was evaluated using Rhamnetin (RHM), a previously characterized LIG3-binding flavonoid, alone or combined with nelarabine across T-ALL cell lines and healthy peripheral blood mononuclear cells. LIG3 mRNA was uniformly expressed across T-ALL oncogenic subgroups. Functional assays confirmed LIG3 essentiality in T-ALL models. RHM dose-dependently reduced viability and clonogenic potential while sparing healthy cells. Mechanistically, RHM triggered a canonical DNA damage response with CHK1/CHK2 phosphorylation and γH2AX accumulation, driving CDC25A down-regulation, cell cycle perturbation, and apoptosis. Furthermore, RHM enhanced the anti-leukemic efficacy of nelarabine, displaying synergistic to additive interactions. These findings suggest LIG3 as an actionable dependency in T-ALL cells and support LIG3 inhibition, alone or combined with nelarabine, for therapeutic development.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7225889574
FWCI:
Cites: 45
Cited by:
Related to: 9